Beta Bionics is a medical device company that designs and sells automated insulin delivery systems for people with insulin-requiring diabetes. Its flagship product, the iLet Bionic Pancreas, is a closed-loop insulin pump that automatically calculates and delivers insulin doses without requiring users to count carbohydrates, and it integrates with leading continuous glucose monitors to provide real-time diabetes management. The company generates revenue primarily through a direct sales organization targeting endocrinology practices, using both traditional durable medical equipment reimbursement models and newer pharmacy benefit plan arrangements that remove upfront patient costs and accelerate adoption. Beta Bionics competes with established insulin pump manufacturers while differentiating on full autonomy, ease of use, and flexible reimbursement options, and it is developing complementary products including a tubeless patch pump and a bihormonal system combining insulin and glucagon to expand its addressable market.